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Inﬂammatory responseSepsis is an infection-induced severe inﬂammatory disorder that leads tomultiple organ failure. Amongst organs
affected, myocardial depression is believed to be a major contributor to septic death.While it has been identiﬁed
that large amounts of circulating pro-inﬂammatory cytokines are culprit for triggering cardiac dysfunction in sep-
sis, the underlyingmechanisms remain obscure. Additionally, recent studies have shown that exosomes released
from bacteria-infected macrophages are pro-inﬂammatory. Hence, we examined in this study whether blocking
the generation of exosomes would be protective against sepsis-induced inﬂammatory response and cardiac dys-
function. To this end, we pre-treated RAW264.7macrophageswith GW4869, an inhibitor of exosomebiogenesis/
release, followed by endotoxin (LPS) challenge. In vivo, we injected wild-type (WT) mice with GW4869 for 1 h
prior to endotoxin treatment or cecal ligation/puncture (CLP) surgery. We observed that pre-treatment with
GW4869 signiﬁcantly impaired release of both exosomes and pro-inﬂammatory cytokines (TNF-α, IL-1β, IL-6)
in RAW264.7 macrophages. At 12 h after LPS treatment or CLP surgery, WT mice pre-treated with GW4869
displayed lower amounts of exosomes and pro-inﬂammatory cytokines in the serum than control PBS-injected
mice. Accordingly, GW4869 treatment diminished the sepsis-induced cardiac inﬂammation, attenuatedmyocar-
dial depression and prolonged survival. Together, our ﬁndings indicate that blockade of exosome generation in
sepsis dampens the sepsis-triggered inﬂammatory response and thereby, improves cardiac function and survival.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Sepsis, a leading cause of death in the intensive care unit (ICU), is a
severe inﬂammatory response syndrome caused by infection [1,2].
Multiple organ dysfunction is a hallmark of this syndrome, with
sepsis-induced cardiomyopathy responsible for a large number of
death cases. Indeed, septic patients with cardiac abnormalities have a
70% chance of mortality compared to 20% mortality rate for patients
withoutmyocardial dysfunction [3,4].While the underlyingmechanism
leading to septic cardiomyopathy remains largely ambiguous, it is well
accepted that circulating pro-inﬂammatory cytokines (i.e., TNF-α, IL-
1β, IL-6) are the myocardial depressive factors (MDFs) [5–8]. Theseacology and Cell Biophysics,
rt Sabin Way, Cincinnati, OHcytokines are mainly produced by macrophages and other leukocytes
through activation of toll-like receptors (TLRs) and subsequent NF-κB
signaling cascades upon septic shock [9–14]. In addition, other inﬂam-
matory mediators such as nitric oxide may stimulate synthesis of pro-
inﬂammatory cytokines in macrophages and cardiomyocytes, and thus
contribute to myocardial depression [15–17].
Recently, exosomes, a type of membrane-bound nanoparticle natu-
rally released from living cells, have been deﬁned asnovel factors tome-
diate the pathogenesis of sepsis [18–20]. Particularly, exosomes isolated
fromplatelets of septic patients inducemyocardial depression in animal
models by promoting the expression of pro-inﬂammatory proteins such
as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX2)
[19,20]. Furthermore, these platelet-derived exosomes promote vascu-
lar dysfunction by inducing the NAD(P)H oxidase-mediated generation
of reactive oxygen species in endothelial cells [21,22]. Therefore, it
would be beneﬁcial for septic patients if exosome secretion from plate-
lets were inhibited. Nevertheless, macrophages are the ﬁrst-line to ﬁght
against sepsis since multiple cardiac depressors (i.e., inﬂammatory
2363K. Essandoh et al. / Biochimica et Biophysica Acta 1852 (2015) 2362–2371cytokines) are produced by macrophages. As a matter of fact,
macrophage-deﬁcientmice appeared to attenuate LPS-causedmyocardial
depression [23]. Additionally, rat cardiomyocytes incubated with LPS-
treated macrophages exhibited a signiﬁcant reduction in contractility,
suggesting a direct cross-talk betweenmacrophages and cardiomyocytes
[24]. Several studies have also implicated macrophages as autocrine and
paracrine signaling mediators that initiate further inﬂammatory re-
sponses in both neighboring macrophages and other types of cells [25,
26]. Recently, exosomes isolated from mycobacterium-treated macro-
phages were found to be pro-inﬂammatory in naive macrophages [27,
28].We thus questionedwhether blockade of exosome release frommac-
rophages and other cell types (i.e., platelets) would be able to attenuate
sepsis-triggered inﬂammation and thereby, improve cardiac function.
Currently, GW4869, a neutral sphingomyelinase inhibitor, is the
most widely used pharmacological agent for blocking exosome genera-
tion [29–32]. GW4869 inhibits the ceramide-mediated inward budding
of multivesicular bodies (MVBs) and release of mature exosomes from
MVBs [30]. It was ﬁrst utilized by Kosaka et al. to successfully inhibit
exosome release in HEK293 cells [29]. In the present study, we deter-
mined the pro-inﬂammatory effects of exosomes derived from LPS-
treated macrophages, and then examined the consequence of
GW4869-mediated inhibition of exosomes on cytokine production in
LPS-treated macrophages in vitro. We next investigated the in vivo ef-
fects of GW4869 on pro-inﬂammatory cytokine production, cardiac
function and mortality in endotoxin-challenged mice and a more clini-
cally relevant sepsis model, induced by cecal ligation and puncture
(CLP) surgery. Our results indicate that the global blockade of exosome
production with GW4869 attenuates sepsis-induced inﬂammation, im-
proves cardiac function and prolongs animal survival.2. Methods and materials
2.1. Animals and macrophage cell line
Male wild-type C57BL/6 mice were purchased from Jackson Labora-
tory (Indianapolis, IN). The mice were maintained and bred in the Divi-
sion of Laboratory Animal Resources at the University of Cincinnati
Medical Center. All the animal experiments conformed to the Guide-
lines for the Care and Use of Laboratory Animals prepared by the Na-
tional Academy of Sciences, published by the National Institutes of
Health, and approved by the University of Cincinnati Animal Care and
Use Committee (Animal Welfare Assurance Number: A3295-01). The
mouse macrophage cell line RAW264.7 was purchased from American
Type Culture Collection (ATCC), Rockville, MD. The macrophages were
maintained in Dulbecco's modiﬁed Eagle's medium (DMEM; Sigma)
containing 15% of fetal bovine serum (FBS; Sigma), 2 mm L-glutamine
(Gibco, USA), 100 u/ml penicillin and 100 u/ml streptomycin (Sigma).
The macrophages were grown at 37 °C with 5% CO2 in fully humidiﬁed
air. Culture mediumwas changed every 1–2 days. Subsequent passages
were performed with a 0.025% Trypsin (Sigma) containing 0.02% EDTA
for 10 min at 37 °C. The fourth passage macrophages were used for ex-
periments in this study.2.2. Treatment of macrophage cell line with LPS
RAW 264.7 macrophages were plated in 100 mm petri dishes at
1.2 × 106 cells/dish. Macrophages were allowed to adhere for 24 h be-
fore any treatments. Macrophages were treated with culture media in
the presence or absence of 1 μg/ml Escherichia coli LPS (Sigma,
0111:B4) and incubated at 37 °C and 5% CO2 for 24 h. Culture superna-
tants were then collected for exosome isolation, acetylcholinesterase
(AChE) activity assay, and cytokinemeasurement. For the exosome col-
lection and function assays, exosome-depleted FBS (System Biosciences
Inc.) was used in the cell culture.2.3. Isolation and characterizations of exosomes
Supernatants from cultured RAW264.7macrophages were collected
on ice and centrifuged at 2000 ×g for 30 min to remove any cells and
cellular debris, and then supernatants were transferred to a fresh tube
and centrifuged at 10,000 ×g for 30min at 4 °C. Subsequently, superna-
tants were transferred to a fresh tube and centrifuged at 100,000 ×g (Ti-
45 rotor) for 10 h at 4 °C. The exosomal pellet was then washed once
with sterile PBS to remove any secreted proteins and re-suspended in
500 μl of PBS. The quality of exosomes was conﬁrmed by dynamic
light scattering using a particle and molecular size analyzer (Zetasizer
Nano ZS,Malvern Instruments) according to themanufacturer's instruc-
tions. The quantity of exosomes was determined by the Micro-BCA
assay (Pierce, Rockford, IL) for measurement of total protein. The pro-
inﬂammatory cytokine content of the isolated exosomes was deter-
mined by ELISA assays. Endotoxin levels in isolated exosomes were
measured to determine possible endotoxin contamination, using the
ToxinSensor Chromogenic LAL Endotoxin kit (Genscript) per the
manufacturer's protocol.
2.4. Western blot analysis
Equal amounts of protein were subjected to SDS-PAGE. Binding of
the primary antibody was detected by peroxidase-conjugated second-
ary antibodies and enhanced chemiluminescence (Amersham
Pharmacia), and bands were quantiﬁed with densitometry. The sources
of antibodies and dilutions used were as follows: rabbit anti-CD63 (sc-
15363, 1:1000 dilution) and rabbit anti-CD81 (sc-9158, 1:1000 dilu-
tion). GAPDH (1:1000 dilution, GeneTex) was used as an internal
control.
2.5. Treatment of macrophages with exosomes or GW4869
Fresh RAW264.7 macrophages were plated in 100 mm petri dishes
at 1.2 × 106 cells/dish, and treated with either culture media containing
20 μg of exosomes isolated from non-LPS treated macrophages (non-
LPS exosomes) or 20 μg of exosomes isolated from LPS treated macro-
phages (LPS exosomes), or exosome-free media. The culture superna-
tants were harvested for cytokine ELISA assays at 10 min and 24 h. For
inhibition of exosome generation, macrophages were pre-treated with
either culture media containing 10 μM or 20 μM GW4869 (Sigma) for
2 h prior to treatmentwith 1 μg/ml LPS incubation, Culture supernatants
were collected after 24 h for AChE activity assay and cytokinemeasure-
ment. GW4869was initially dissolved in DMSO (Fisher Scientiﬁc) into a
stock solution of 5 mM GW4869 before dilution in culture supernatant
to achieve 10 μMor 20 μMGW4869 concentration in cell culture condi-
tion (note: ﬁnal DMSO concentration is 0.005%). To determine the pos-
sible toxicity of DMSO or GW4869, fresh RAW 264.7 macrophages
(1.2 × 106 cells/dish) were incubated in culture media containing
0.005% DMSO, 10 μMGW4869 and 20 μM GW4869 for 24 h. Cell injury
was determined by measuring the release of lactase dehydrogenase
(LDH) into the culturemedia, using a LDH detection kit (Sigma) accord-
ing to the manufacturer's protocol.
2.6. GW4869 treatment in endotoxin-challenged mice
Wild-type male C57BL/6 mice were studied at 10 to 12 weeks old.
The mice were randomly assigned to four groups: PBS, GW4869,
PBS + LPS and GW4869 + LPS (n = 5 per group). GW4869, dissolved
in DMSO (0.005%), was intraperitoneally (i.p.) injected at one dose of
2.5 μg/g. Mice in the PBS + LPS group were pre-injected i.p. with PBS
1 h prior to an i.p. injection of LPS (25 μg/g). Mice in the group of
GW4869 + LPS were pre-injected i.p. with GW4869 (2.5 μg/g) for 1 h,
followed by an i.p. injection of LPS (25 μg/g, 100 μl). Mice received injec-
tions of PBS to a comparable volume (100 μl) as controls. The survival
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6 h for a 36 h period.
2.7. Pre-treatment with GW4869 in CLP polymicrobial sepsis model
Polymicrobial sepsis was surgically induced by cecal ligation and
puncture (CLP) as previously described [33]. Wild-type C57BL/6 mice
(10–12 weeks, male) were randomly assigned to four groups:
PBS+ Sham, GW4869 + Sham, PBS+ CLP and GW4869+ CLP. Before
sham or CLP surgery, mice were administered by intraperitoneal (i.p.)
injection at one dose of GW4869 (2.5 μg/g). Same volume of PBS was
injected as controls. For CLP surgery, mice were anesthetized by
isoﬂurane inhalation and ventilated with room air using a rodent venti-
lator. A 1- to 2-cm midline incision was made below the diaphragm to
expose the cecum. The cecum was ligated at 1.0 cm from the tip with
a 5-0 sterile silk suture. A single through and through puncture was
made at the middle between the ligation and the tip of the cecum with
an 18-gauge to induce severe septic injury. After puncturing, the cecum
was gently squeezed to extrude a small amount of feces and returned to
the abdominal cavity. The abdominal wall incision was closed in layers.
After surgery, pre-warmed normal saline (0.05–0.1 ml/g body weight)
was administered subcutaneously. Post-operative pain control was man-
aged with subcutaneous injection of bupivacaine and buprenorphine.
Sham controls were exposed to the same surgery; however, their
cecum was neither ligated nor punctured. The survival rate of the
PBS + CLP and the GW4869 + CLP groups was monitored every 6 h for
2 days.
2.8. Assessment of AChE activity, cytokine and myeloperoxidase (MPO)
Activity
AChE activity was used to indirectly determine the quantity of
exosomes in culture supernatants or sera, because acetylcholinesterases
are localized to the membrane of exosomes [34]. The AChE activity was
determined using a commercially available AChE activity assay kit
(Sigma). Culture supernatants and serum samples were incubated in
the working reagent in 96-well plates. After incubation, the colometric
product was read at 412 nm on a microplate reader and expressed as
AChE activity (units/l) per the manufacturers' instructions. The levels
of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6) and interleukin
1β (IL-1β) in the sera and culture supernatants were determined, using
commercially available ELISA kits (Bio-legend). Cytokine levels were
established by comparison to a standard curve per the manufacturer's
instructions. Myeloperoxidase (MPO) activity was measured using
commercial MPO Elisa kit (Abnova). MPO, which is released upon neu-
trophil inﬁltration, enhances tissue inﬂammation through the release of
cytotoxic oxidants [35]. Heart samples were homogenized in ice-cold
lysis buffer and centrifuged at 12,000 ×g for 10 min, after which super-
natants were used for the MPO activity assay. The MPO kit utilizes a
sandwich enzyme-linked immune-sorbent assaymethod, withMPO ac-
tivity measured at 450 nm on a microplate reader in comparison to a
standard curve.
2.9. Assessment of cardiac function in vivo
Cardiac functionwas assessed in vivousing trans-thoracic echocardi-
ography (Vevo®2100 Imaging System, Visualsonics) with a 15-MHz
probe. Left ventricular (LV) end-diastolic (LVDd) and end-systolic diam-
eters (LVDs)weremeasured fromM-mode recordings. LV function var-
iables were assessed at 12 h after LPS administration and 12 h after
sham/CLP surgery. LV ejection fraction (EF) was calculated as:
[(LVDd3− LVDs3) / LVDd3] × 100. LV fractional shortening (FS%) was
determined as [(LVDd − LVDs) / LVDd] × 100. All measurements
were performed according to the American Society for Echocardiology
leading-edge technique standards, and average over three consecutive
cardiac cycles.2.10. Statistical analysis
Data were expressed asmeans± SEM. Signiﬁcance was determined
by Student t test, and one- or two-way analysis of variance was appro-
priate to determine differences within groups, with a Bonferroni post
hoc analysis. The survival rates were constructed using the Kaplan–
Meier method, and differences in mortality were compared using the
log-rank-test. A P b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. LPS treatment increases exosome release and pro-inﬂammatory cyto-
kine production in macrophages in vitro
A number of studies have indicated that bacterial infection can stim-
ulate exosomes and pro-inﬂammatory cytokine release from macro-
phages [27,28]. To validate these observations, we treated RAW264.7
macrophages with E. coli LPS, and measured the amount of exosomes
and pro-inﬂammatory cytokines in the culture supernatant. We ob-
served a signiﬁcantly higher activity of the AChE, a speciﬁc enzyme as-
sociated with exosome membrane, in the supernatants of LPS-treated
macrophages compared to control macrophages (Fig. 1A). Further, the
protein concentration in exosomes isolated from LPS treated macro-
phages (LPS exosomes) was signiﬁcantly higher than protein quantities
in ‘non-LPS exosomes’ (Fig. 1B). Results of ELISA analysis showed that
LPS treatment caused a 7-fold increase in TNF-α, 4.5-fold increase in
IL-1β and 616-fold increase in IL-6 levels compared to non-treatedmac-
rophages (Fig. 1C–E). These data indicate that endotoxin can stimulate
macrophages to release exosomes, together with the secretion of pro-
inﬂammatory cytokines.
3.2. Exosomes derived from LPS treatedmacrophages are pro-inﬂammatory
To explore the possible properties of ‘LPS exosomes’, we ﬁrst charac-
terized exosomes isolated from LPS-treated macrophages and non-LPS-
treated macrophages. Using dynamic light scattering, we observed that
the average size of exosomes derived from LPS-treated macrophages
(43.82 nm) was similar to the size of exosomes derived from non-LPS-
treated macrophages (43.88 nm) (Fig. 2A). Moreover, western blot
analysis of exosomal proteins revealed the presence of CD63 and
CD81, two exosomal markers, in both LPS exosomes and non-LPS
exosomes (Fig. 2B). Endotoxin levels in non-LPS and LPS exosomes
were extremely low and negligible (b0.1 EU/ml, b0.0002 EU/μg of
exosomal protein) compared to levels in culture medium from LPS-
treated macrophages (Supplemental Fig. 1a/b). Interestingly, the con-
tent of TNF-α and IL-6 in LPS exosomes was signiﬁcantly higher than
non-LPS exosomes (Fig. 2C/E), although levels of IL-1β were similar in
both exosomes (Fig. 2D). To elucidate whether LPS exosomes are pro-
inﬂammatory, we treated fresh RAW264.7 macrophages with 20 μg of
respective exosomes for 24 h, and then performed cytokine analysis in
the culture supernatant. To eliminate the possibility that the pro-
inﬂammatory cytokines in the culture supernatant after 24 h might be
attributed to the initial cytokine content of exosomes, culture superna-
tant was also collected 10 min after treatment with both sets of
exosomes. We observed that, while TNF-α and IL-6 levels were signiﬁ-
cantly higher even after 10 min incubation of LPS exosomes compared
to non-LPS exosomes, they were much higher (0.37-fold increase in
TNF-α and 10-fold increase in IL-6 levels) in the supernatants ofmacro-
phages incubated with LPS exosomes after 24 h compared to levels
after 10 min (Fig. 2F/G). Of note, IL-1β levels were too low to detect
in these sets of experiments, and non-LPS exosomes also induced a
smaller increase in TNF-α (but not IL-6) after 24 h incubation com-
pared to levels after 10 min incubation (Fig. 2F). Put together, these
results afﬁrm that exosomes derived from LPS-treated macrophages
are pro-inﬂammatory.
Fig. 1. LPS treatment enhances the release of exosomes and pro-inﬂammatory cytokines from RAW264macrophages. (A) The amount of exosomes was signiﬁcantly increased in macro-
phages (RAW264.7 cells) upon LPS stimulation, evidenced by the increase in acetylcholinesterase (AChE) activity. (B) Protein concentration in exosomes derived fromLPS stimulatedmac-
rophageswas signiﬁcantly greater than exosomes derived fromnon-LPS treatedmacrophages. (C–E) LPS stimulation signiﬁcantly elevated levels of inﬂammatory cytokines TNF-α (C), IL-
1β (D) and IL-6 (E) in RAW264.7 macrophages. n = 3; *, P b 0.05 vs. non-LPS.
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production in macrophages
Next, we sought to determine if blockade of exosome generation
would diminish the LPS-mediated pro-inﬂammatory responses in
RAW264.7 macrophages. GW4869 has been successfully used to block
the secretion of exosomes from HEK293 cells, cardiomyocytes, liver cells
and lung epithelial cells [29–32]. In this study,we treatedRAW264.7mac-
rophages with two different doses of GW4869 (10 μM and 20 μM). We
observed that LPS-triggered exosome generationwas remarkably attenu-
ated in macrophages upon pre-treatment of macrophages with 10 μM
GW4869, as evidenced by a 22% reduction in the activity of AChE
(Fig. 3A). Such attenuation was further enhanced by treatment with
20 μM GW4869 (Fig. 3A). To test the possible toxicity of GW4869, we
measured the levels of lactase dehydrogenase (LDH), a marker of cell in-
jury, in the supernatants of macrophages upon exposure to 10 μM and
20 μM GW4869, as well as 0.005% DMSO (solution used to dissolve
GW4869) for 24 h. Our results showed that LDH levels were similar in
0.005% DMSO, 10 μM GW4869, 20 μM GW4869 and non-treated groups
(Fig. 3B). This suggests that 0.005% DMSO and GW4869 do not have
toxic effects onmacrophages. Assessment of pro-inﬂammatory cytokines
revealed a signiﬁcant decrease in the levels of TNF-α, IL-1β and IL-6 by
16.4%, 62%, and 15.6% respectively, in the supernatants of GW4869-
treated macrophages upon LPS challenge, compared to control macro-
phages treated with LPS only (Fig. 3C–E). Collectively, these data indicate
that GW4869 suppresses the endotoxin-triggered generation of
exosomes in RAW264.7 macrophages and subsequently, decreases the
production of pro-inﬂammatory cytokines.3.4. Inhibition of exosome release blocks LPS-stimulated pro-inﬂammatory
cytokine production and cardiac inﬂammation in mice
To determine the in vivo effects of GW4869, WT mice were injected
i.p. with either PBS or GW4869 (2.5 μg/g) for 1 h, followed by LPSinjection at one dose of 25 μg/g. 12 h later, levels of serum exosomes
and pro-inﬂammatory cytokines, as well as myocardial inﬂammation
were assessed. We noticed that, under basal conditions, GW4869 treat-
ment signiﬁcantly decreased exosome levels by 37% in sera, compared
to levels collected fromcontrolmice (Fig. 4A). At 12h after LPS injection,
the levels of circulating exosomes were increased signiﬁcantly com-
pared to PBS-controls, as evidenced by a 1.7-fold elevation in the
AChE activity (Fig. 4A). However, such LPS-induced elevation of serum
exosomes was signiﬁcantly inhibited in mice subjected to pre-
treatment with GW4869, compared to the PBS + LPS group (Fig. 4A).
Accordingly, pre-treatment with GW4869 resulted in a signiﬁcant de-
crease in endotoxin-triggered production of pro-inﬂammatory cyto-
kines (TNF- α, IL-1β and IL-6) in the serum, as evidenced by a 17%
reduction of TNF-α (Fig. 4B), 11% decrease of IL-1β (Fig. 4C), and 28% re-
duction of IL-6 (Fig. 4D), compared to the PBS+ LPS group. Also, we ob-
served that MPO activity was signiﬁcantly reduced by 12% in the hearts
of mice pre-treated with GW4869 upon LPS challenge, compared to
mice pre-treated with PBS. This indicates that LPS-caused inﬁltration
of neutrophils into the myocardium is suppressed by GW4869
(Fig. 4E). Taken together, our results suggest that pre-treatment of WT
mice with GW4869 could attenuate LPS-triggered production of
exosomes and pro-inﬂammatory cytokines in the blood which subse-
quently reduces myocardial inﬂammation.
3.5. GW4869 mitigates LPS-caused myocardial dysfunction and improves
survival in mice
It is well recognized that the production of circulating pro-
inﬂammatory cytokines mediates myocardial dysfunction during septic
shock [5–8]. Given the inhibitory effects of GW4869 on production of
pro-inﬂammatory cytokines and cardiac inﬂammation, we next evalu-
ated the effects of GW4869 on endotoxin-induced cardiac dysfunction.
WT mice were treated with either PBS or GW4869 (2.5 μg/g) for 1 h,
followed by LPS injection at one does of 25 μg/g. Cardiac function was
assessed by echocardiography. Consistent with previous observations,
Fig. 2. Effects of exosomes derived from LPS-treatedmacrophages on naïve RAW264.7macrophages. Exosomeswere isolated from the culture supernatants of RAW264.7 cells in the pres-
ence or absence of LPS, using differential centrifugation. (A) The size of exosomes wasmeasured by dynamic light scattering, using a particle andmolecular size analyzer (Zetasizer Nano
ZS, Malvern Instruments). (B) Exosomal markers (CD63 and CD81) were expressed in both non-LPS exosomes and LPS exosomes. Levels of TNF-α (C) and IL-6 (E) in LPS exosomes were
signiﬁcantly higher than levels in non-LPS exosomes while levels of IL-1β (D) were similar in both exosomes. n = 4; *, P b 0.05 vs. non-LPS exosomes. (F/G) LPS exosomes stimulated
signiﬁcantly higher levels of TNF-α (F) and IL-6 (G) after 24 h than 10 min incubation. Notably, non-LPS exosomes also stimulated a small increase in TNF-α levels after 24 h compared
to 10 min incubation. n = 4; $, P b 0.05 vs. 10 min (non-LPS Exo); #, P b 0.05 vs. Ctl; *, P b 0.05 vs. 10 min (LPS Exo).
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to controls (Fig. 5A–C). However, pre-treatment of mice with
GW4869 evoked an improvement of cardiac function, evidenced by
a signiﬁcant increase in left ventricular ejection fraction (EF%) and
fractional shortening (FS%), compared to LPS-injected mice pre-
treated with PBS controls (Fig. 5A–C, and Supplemental Table 1). At
36 h post-LPS injection, only 16.7% of mice pre-treated with PBS
(n = 12) survived whereas 66.7% of mice pre-treated with
GW4869 (n = 9) survived (Fig. 5D). Collectively, our data indicatethat blockade of exosome generation with GW4869 diminishes the
endotoxin-caused myocardial dysfunction and decreases mortality
in mice.
3.6. GW4869 blocks the production of pro-inﬂammatory cytokines and car-
diac inﬂammation in CLP mice
We next examined whether the GW4869-mediated protective ef-
fects can be replicated in a clinical-relevant septic model, induced by
Fig. 3.Effects of GW4869on exosome release and pro-inﬂammation cytokine production in LPS-treatedRAW264.7macrophages. (A) LPS-stimulated exosome generationwas signiﬁcantly
inhibited by addition of 10 μM and 20 μM GW4869 to cultured RAW264.7 cells. n = 3; #, P b 0.05 vs.Medium; *, P b 0.05 vs. LPS. (B) 0.005% DMSO, 10 μM and 20 μM GW4869 had no
cytotoxic effects on RAW 264.7 cells, shown by similar levels of lactase dehydrogenase (LDH) in all treatments compared to non-treated group. (C–E) Pre-treatment with GW4869 sig-
niﬁcantly reduced levels of (C) TNF-α, (D) IL-1β and (E) IL-6 from LPS-treated macrophages. Control macrophages were pre-treated with 0.005% DMSO. n = 3 wells; *, P b 0.05. Similar
results were observed from three independent experiments.
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GW4869 (2.5 μg/g), followed by CLP or sham surgery. The levels of
exosomes and pro-inﬂammatory cytokines in the serum, as well as
myocardial inﬂammation, were determined at 12 h after the surgery.
In sham-surgery controls, pre-treatment with GW4869 decreased
exosome concentration by 33% compared to mice injected with PBS
(Fig. 6A). Similar to endotoxin challenge, CLP surgery caused aFig. 4.Effects ofGW4869pre-treatment on exosome release, pro-inﬂammatory cytokine produc
with GW4869 (2.5 μg/g) signiﬁcantly inhibited serum exosome concentration in PBS-treated m
inﬂammation were dampened by blockade of exosome release, as evidenced by reduced serum
MPO assays; $, P b 0.05 vs. PBS; #, P b 0.05 vs. PBS; *, P b 0.05 vs. PBS + LPS.signiﬁcant elevation in the levels of serum exosomes, as measured
by AChE activity (Fig. 6A). Importantly, such CLP-stimulated
exosome release was signiﬁcantly inhibited by pre-treatment of
CLP mice with GW4869, compared to CLP mice pre-treated with
PBS (Fig. 6A). The results of pro-inﬂammatory cytokine analysis in
the serum revealed a signiﬁcant decrease in the levels of TNF-α by
85% (Fig. 6B) and IL-6 by 46% (Fig. 6C) in CLP-mice pre-treatedtion in the serumandmyocardial inﬂammation in LPS-treatedWTmice. (A) Pre-treatment
ice and LPS-treatedmice. Accordingly, LPS-stimulated inﬂammatory response and cardiac
levels of TNF-α (B), IL-1β (C), IL-6 (D) and cardiac MPO activity (E). n = 5 for ELISA and
Fig. 5. Effects of GW4869 pre-treatment on endotoxin-induced cardiac dysfunction and survival. (A) Representative images of echocardiography showed that LPS-triggered car-
diac dysfunctionwas attenuated in GW4869-pre-treatedmice, as measured by left ventricular ejection fraction (EF%) (B), and fractional shortening (FS%) (C). n= 6–11 for echo-
cardiography; #, P b 0.05 vs. PBS; *, P b 0.05 vs. PBS+ LPS. (D) Pre-treatment of mice with GW4869 signiﬁcantly improved animal survival after LPS injection, compared with PBS-
pre-treated mice; *, P b 0.05, n = 9–12.
2368 K. Essandoh et al. / Biochimica et Biophysica Acta 1852 (2015) 2362–2371with GW4869, compared to the PBS+ CLP group. CLP-induced cardi-
ac inﬂammation, assessed by MPO activity, was greatly alleviated in
the GW4869 + CLP group, compared to the PBS + CLP samplesFig. 6. Effects of GW4869 pre-treatment on exosome release, pro-inﬂammatory cytokine produ
(2.5 μg/g) signiﬁcantly inhibited serum exosome concentration in sham- and CLP-mice. Accord
blockade of exosome release, as evidenced by reduced serum levels of TNF-α (B) and IL-6 (
PBS + Sham; *, P b 0.05 vs. PBS + CLP.(Fig. 6D). Hence, our data suggest that GW4869 could inhibit the
CLP-triggered production of pro-inﬂammatory cytokines in serum
and myocardial inﬂammation.ction in the serum and cardiac inﬂammation in CLP mice.(A) Pre-treatment with GW4869
ingly, CLP-induced inﬂammatory response and cardiac inﬂammation were dampened by
C) and myocardial MPO activity (D). n = 5; $, P b 0.05 vs. PBS + Sham; #, P b 0.05 vs.
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and improves survival
To determine the effects of GW4869-mediated blockade of exosome
generation on myocardial dysfunction in CLP mice, we pre-treated WT
mice with either PBS or GW4869 prior to CLP surgery, with sham oper-
ation used as controls. At 12 h post-CLP surgery, myocardial function
was depressed, as evidenced by a remarkable reduction of left ventricu-
lar ejection fraction (EF%) and fractional shortening (FS%) in PBS+ CLP
mice, compared to sham controls (Fig. 7A–C and Supplemental Table 2).
However, such CLP-caused myocardial depression was attenuated by
GW4869 pre-treatment (Fig. 7A–C and Supplemental Table 2). Accord-
ingly, pre-treatmentwith GW4869 had a beneﬁcial impact onmortality
of the mice that underwent CLP surgery. At 48 h post-CLP surgery, only
6.25% of mice pre-treatedwith PBS (n=16) survived, whereas 66.7% of
mice pre-treated with GW4869 (n = 12) survived (Fig. 7D). Taken to-
gether, these data indicate that GW4869-mediated blockade of
exosome generation alleviates the CLP-inducedmyocardial dysfunction
and improves survival.
4. Discussion
The present study was conceptualized to determine the effects of
blocking exosome release on the production of pro-inﬂammatory cy-
tokines and sepsis-induced myocardial dysfunction. We demon-
strated that GW4869 could effectively inhibit the generation of
exosomes in macrophages and in vivo. Importantly, we discovered
that GW4869 suppressed the production of pro-inﬂammatory cyto-
kines in LPS-treated RAW264.7 macrophages in vitro and sepsis-
caused inﬂammatory response in vivo. As a result, sepsis-induced
cardiac dysfunction and mortality were attenuated by GW4869
pre-treatment. Therefore, our study presented here may provide a
novel approach to the treatment of sepsis.
Sepsis is characterized by a severe cytokine storm where high
amounts of pro-inﬂammatory cytokines can be detected in circulation
[13]. It is well accepted that sepsis-caused multiple organ failure is at-
tributed to the prolonged cytokine storm [1,2]. Especially, these circu-
lating pro-inﬂammatory cytokines could result in the development of
myocardial dysfunction, which contributes to about 250,000 deathsFig. 7. Effects of GW4869 pre-treatment on CLP-induced cardiac dysfunction and survival. (A) CL
signiﬁcant improvement of LVEF% (B) and LVFS% (C), compared to PBS-treated controls; n = 6
treatment of mice with GW4869 signiﬁcantly improved animal survival after CLP surgery, comannually [36,37]. However, clinical trials using anti-inﬂammatory
agents (i.e., TNF inhibitors) have largely been unsuccessful in improving
the survival rate of sepsis patients [2]. Hence, there might be other fac-
tors contributing to the exaggeration of the cytokine storm. Indeed, we
observed in this study that there was a remarkable increase in circulat-
ing exosomes besides the elevation of pro-inﬂammatory cytokine
levels. Our data also showed that exosomes derived from LPS-treated
macrophages are pro-inﬂammatory and could stimulate naïve macro-
phages to releasemuchmore inﬂammatory cytokines, leading to a pos-
itive feed-back mechanism and exaggerated inﬂammatory response.
Therefore, septic exosomes may be culpable for enabling the cytokine
storm during severe sepsis.
Recently, exosomes have been receiving enormous attention due to
their involvement in the progression of pathological/physiological con-
ditions such as inﬂammation, tumorigenesis, angiogenesis and coagula-
tion [18,30,38–40]. In the sepsis setting, high amounts of exosomes
have been reported in the plasma of septic patients compared to healthy
individuals [20]. Importantly, exosomes derived from platelets of septic
patients caused depression of rat cardiomyocyte contractility [20]. Nev-
ertheless, it remains unclear whether blocking the generation of
exosomes could offer protection against sepsis injury. Considering that
macrophages are a major source of pro-inﬂammatory cytokines and
play a critical role in the pathogenesis of sepsis, we thus selectedmacro-
phages as the model cell to investigate the possible effects of reduced
exosome secretion on cytokine production. In this study, we employed
GW4869 as an inhibitor of exosome generation, since it has been uti-
lized to prevent the production of exosomes in a variety of cells
[29–32]. Consistently, we observed that GW4869 could effectively sup-
press the secretion of exosomes from LPS-challenged macrophages,
which was accompanied by reduction of pro-inﬂammatory cytokines.
As such, we propose an autocrine signaling of macrophage-derived
exosomes on neighboring macrophages, which magniﬁes the amount
of pro-inﬂammatory cytokines produced by the initial bacterial LPS
stimulation (Fig. 8). Similarly, pre-treatment of endotoxemic and
polymicrobial septicmicewithGW4869 caused a reduction in the levels
of circulating exosomes and pro-inﬂammatory cytokines. As a conse-
quence, sepsis-induced cardiomyopathy wasmitigated and animal sur-
vival was improved in GW4869-pre-treated mice. Therefore, our data
may provide the ﬁrst evidence that blockade of exosome generationP-induced cardiac dysfunctionwas attenuated inGW4869-treatedmice, as evidenced by a
–11 for echocardiography; #, P b 0.05 vs. PBS + Sham; *, P b 0.05 vs. PBS + CLP. (D) Pre-
pared with PBS-pre-treated mice; *, P b 0.05, n = 12–16.
Fig. 8. Proposed scheme depicting the role of exosomes in sepsis. CLP surgery or bacterial LPS infection can induce the release of exosomes and pro-inﬂammatory cytokines frommacro-
phages and other cell types. Themacrophage-derived exosomes act as autocrine and paracrine signalmediators by inducing further synthesis of pro-inﬂammatory cytokines in the original
macrophages and neighboring macrophages. Such over-production of inﬂammatory cytokinesmay partially impair cardiac function. Exosomes derived frommacrophages and other cell
types (i.e., platelets)may also directly depressmyocardial contraction during sepsis. All these communication lines could be cut off byGW4869-mediated blockade of exosomegeneration,
leading to attenuation of sepsis-induced cardiac inﬂammation and dysfunction.
2370 K. Essandoh et al. / Biochimica et Biophysica Acta 1852 (2015) 2362–2371could inhibit inﬂammatory response, improve cardiac function and pro-
long animal survival in sepsis.
There is growing evidence to support exosomes as vehicles to re-
lease cell-associated cytokines [41–43]. In the present study, LPS
exosomes possessed higher quantities of TNF-α and IL-6 compared to
control exosomes. Notwithstanding, LPS exosomes appeared to trigger
further production of pro-inﬂammatory cytokines in freshmacrophages
(Fig. 2F/G). Mechanistically, the higher pro-inﬂammatory cytokine con-
tent of LPS exosomes may act as signaling molecules to evoke produc-
tion of more cytokines in neighboring macrophages, or stimulate the
transcription of inﬂammatorymediators [44]. In addition, LPS exosomes
has been shown to stimulate a pro-inﬂammatory response through TLR/
MyD88-dependentmanner [27]. Of course, LPS exosomesmay incorpo-
rate a speciﬁc set of pro-inﬂammatory miRNAs and proteins, although
such analysis may fall outside the scope and intent of this report. None-
theless, all these observations consistently suggest that exosomes de-
rived from LPS-treated cells are pro-inﬂammatory. Another fascinating
observation from our study was the ability of non-LPS exosomes to in-
duce a signiﬁcant increase in TNF-α levels after 24 hour incubation
(Fig. 2F/G). Regardless, the amount of TNF-α produced by the non-LPS
exosome-treated macrophages was minuscule compared to the effects
of LPS exosomes (Fig. 2F/G). This observation suggests that macro-
phages may maintain their basic inﬂammatory property through
exosomes.
It is worth mentioning that, although GW4869 caused a modest re-
duction of circulating pro-inﬂammatory cytokines and cardiac inﬂam-
mation, there was a remarkable rescue of cardiac function in both
endotoxemic and CLP septic models. This indicates that there are addi-
tional effects other than reduction of inﬂammatory response contribut-
ing to GW4869-induced beneﬁts in vivo. Indeed, other cardiac
depressors (miRNAs and proteins) carried with exosomes might have
been suppressed by GW4869. Furthermore, in vivo global treatment of
mice with GW4869 may not only inhibit exosome release from macro-
phages, but also from neutrophils, platelets, endothelial cells and other
cells (Fig. 8). As a matter of fact, it has been observed that platelet-
derived exosomes from septic patients directly impaired cardiac con-
tractile function in animal models via the transfer of exosomal contents
(NADPH, NOS, PDI, ICAM-1 and others) to cardiomyocytes [18–23].
Therefore, the beneﬁcial effects of GW4869 on cardiac function, as pre-
sented in this study, may be ascribed to not only the reduction of pro-
inﬂammatory exosomes, but also the reduction of cardiac-depressing
exosomes. Additionally, effects of GW4869 beyond blockade of
exosomes generation cannot be excluded. Finally, hemodynamic chang-
es play amajor role in sepsis pathophysiology, and thusmay impact car-
diac performance, and eventually cardiac function parameters, ejectionfraction and fractional shortening. As such, it can be difﬁcult to ascertain
whether sepsis-induced cardiac dysfunction is a consequence of sys-
temic hemodynamic changes or intrinsic load-independent myocardial
depression. Nevertheless, septic mice pre-treated with GW4869 had
higher preload and stroke volumes (Supplemental Tables 1 and 2), sug-
gesting the beneﬁcial effects of GW4869 on both load-independent car-
diac contractility and systemic hemodynamic changes, possibly due to
reduction of both systemic and cardiac inﬂammation.
In conclusion, we demonstrate in this study that macrophage-
derived exosomes are pro-inﬂammatorywhichmaypartially contribute
to myocardial inﬂammation and depression during septic shock.
Preventing the generation of these ‘harmful exosomes’ has the capabil-
ity to dampen systemic inﬂammation, attenuate sepsis-induced cardiac
dysfunction and improve survival (Fig. 8). Our study suggests that
interrupting such cell-to-cell communication by either blockade of
exosome generation or with engineered/artiﬁcial exosomes could be
valuable therapeutic strategies in patients with septic shock.
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